Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:47am, Monday, 16'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 02'nd Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 29'th Aug 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more a
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:41am, Thursday, 29'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
10:01am, Thursday, 29'th Aug 2024
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
04:05pm, Wednesday, 28'th Aug 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan St
Why Exelixis (EXEL) Might be Well Poised for a Surge
01:20pm, Monday, 26'th Aug 2024
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis Earnings Drive Share Growth
08:09am, Friday, 16'th Aug 2024
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
3 Stocks to Buy for a Soft Landing, If There Is One
10:35am, Thursday, 15'th Aug 2024
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose.
4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)
12:45pm, Tuesday, 13'th Aug 2024
Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 13'th Aug 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attract
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
10:45am, Tuesday, 13'th Aug 2024
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
10:21am, Monday, 12'th Aug 2024
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
04:04pm, Thursday, 08'th Aug 2024
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product reve
Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impact
02:58pm, Wednesday, 07'th Aug 2024
LEMONT, Ill.--(BUSINESS WIRE)--The tool — free to all users — estimates energy consumption for a wide range of vehicles, both current and future.
